{
  "id": 5067,
  "text": "J Clin Oncol.2019;37:2825-2834.13 Coleman RL, Lorusso D, Gennigens C, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/ GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: J Clin Oncol.2019;37:2825-2834.13 Coleman RL, Lorusso D, Gennigens C, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/ GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "根据当前信息，Tisotumab Vedotin 是一种针对既往治疗后复发或转移性宫颈癌的药物，已在一项多中心、开放标签的单臂 II 期研究（innovaTV 204/GOG-3023/ENGOT-cx6）中显示出疗效和安全性。研究评估了其在既往接受过治疗的患者中的作用，并表明该药物能提供有效的肿瘤控制，同时其安全性处于可接受范围。",
  "query": "根据给定的 <text>，生成的问题如下：\n\n**有哪些针对既往治疗后复发或转移性宫颈癌的药物研究显示了疗效和安全性？**",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 根据给定的 <text>，生成的问题如下：\n\n**有哪些针对既往治疗后复发或转移性宫颈癌的药物研究显示了疗效和安全性？**\n\n<reference text>: J Clin Oncol.2019;37:2825-2834.13 Coleman RL, Lorusso D, Gennigens C, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/ GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "根据当前信息，Tisotumab Vedotin 是一种针对既往治疗后复发或转移性宫颈癌的药物，已在一项多中心、开放标签的单臂 II 期研究（innovaTV 204/GOG-3023/ENGOT-cx6）中显示出疗效和安全性。研究评估了其在既往接受过治疗的患者中的作用，并表明该药物能提供有效的肿瘤控制，同时其安全性处于可接受范围。"
}